Role of HDAC2 in the Pathophysiology of COPD

被引:228
作者
Barnes, Peter J. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England
关键词
histone acetylation; histone deacetylase; macrophage; theophylline; oxidative stress; nuclear factor-kappa B; OBSTRUCTIVE PULMONARY-DISEASE; HISTONE DEACETYLASE ACTIVITY; RELATIVE CORTICOSTEROID INSENSITIVITY; FACTOR-KAPPA-B; OXIDATIVE STRESS; ALVEOLAR MACROPHAGES; EXHALED; 8-ISOPROSTANE; NITRIC-OXIDE; ASTHMA; INFLAMMATION;
D O I
10.1146/annurev.physiol.010908.163257
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Chronic obstructive pulmonary disease (COPD), characterized by progressive inflammation in the small airways and lung parenchyma, is mediated by the increased expression of multiple inflammatory genes. The increased expression of these genes is regulated by acetylation of core histones, whereas histone deacetylase 2 (HDAC2) suppresses inflammatory gene expression. In COPD, HDAC2 activity and expression are reduced in peripheral lung and in alveolar microphages, resulting in amplification of the inflammatory response. Corticosteroid resistance in COPD occurs because corticosteroids use HDAC2 to switch off activated inflammatory genes. The reduction in HDAC2 appears to be secondary to the increased oxidative and nitrative stress in COPD lungs. Antioxidants and inhibitors of nitric oxide synthesis may therefore restore corticosteroid sensitivity in COPD, but this can also be achieved by low concentrations of theophylline and curcumin, which act as HDAC activators.
引用
收藏
页码:451 / 464
页数:14
相关论文
共 76 条
  • [11] Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase
    Barnes, PJ
    Ito, K
    Adcock, IM
    [J]. LANCET, 2004, 363 (9410) : 731 - 733
  • [12] COPD: current therapeutic interventions and future approaches
    Barnes, PJ
    Stockley, RA
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2005, 25 (06) : 1084 - 1106
  • [13] Medical progress: Chronic obstructive pulmonary disease.
    Barnes, PJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (04) : 269 - 280
  • [14] Prospects for new drugs for chronic obstructive pulmonary disease
    Barnes, PJ
    Hansel, TT
    [J]. LANCET, 2004, 364 (9438) : 985 - 996
  • [15] Chronic obstructive pulmonary disease: molecular and cellular mechanisms
    Barnes, PJ
    Shapiro, SD
    Pauwels, RA
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (04) : 672 - 688
  • [16] How do corticosteroids work in asthma?
    Barnes, PJ
    Adcock, IM
    [J]. ANNALS OF INTERNAL MEDICINE, 2003, 139 (05) : 359 - 370
  • [17] BARNES PJ, 2008, J CLIN INVE IN PRESS
  • [18] BARNES PJ, 2004, J COPD, V1, P59
  • [19] Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma
    Bhavsar, P.
    Hew, M.
    Khorasani, N.
    Torrego, A.
    Barnes, P. J.
    Adcock, I.
    Chung, K. F.
    [J]. THORAX, 2008, 63 (09) : 784 - 790
  • [20] Bowler Russell P, 2004, COPD, V1, P255, DOI 10.1081/COPD-200027031